Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The portfolio includes foundational patents on the production, composition, and commercial use of NR
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
NUFYMCO BLA has been approved by the USFDA
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Subscribe To Our Newsletter & Stay Updated